WO2007001332A3 - Anti-pathogen immunoadhesins - Google Patents

Anti-pathogen immunoadhesins Download PDF

Info

Publication number
WO2007001332A3
WO2007001332A3 PCT/US2005/027944 US2005027944W WO2007001332A3 WO 2007001332 A3 WO2007001332 A3 WO 2007001332A3 US 2005027944 W US2005027944 W US 2005027944W WO 2007001332 A3 WO2007001332 A3 WO 2007001332A3
Authority
WO
WIPO (PCT)
Prior art keywords
pathogen
binding domain
tlr
immunoadhesins
protein
Prior art date
Application number
PCT/US2005/027944
Other languages
French (fr)
Other versions
WO2007001332A2 (en
Inventor
Alberto Visintin
Douglas T Goldenbock
Original Assignee
Univ Massachusetts
Alberto Visintin
Douglas T Goldenbock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts, Alberto Visintin, Douglas T Goldenbock filed Critical Univ Massachusetts
Priority to US11/659,154 priority Critical patent/US8080245B2/en
Publication of WO2007001332A2 publication Critical patent/WO2007001332A2/en
Publication of WO2007001332A3 publication Critical patent/WO2007001332A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), Mannan-binding lectin (MBL), or complement C1q globular binding domain, an optional linker, and an Fc portion of an antibody are described and are useful for, e.g., drug discovery and treatment of conditions related to TLR signaling.
PCT/US2005/027944 2004-08-04 2005-08-04 Anti-pathogen immunoadhesins WO2007001332A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/659,154 US8080245B2 (en) 2004-08-04 2005-08-04 Anti-pathogen immunoadhesins

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59877404P 2004-08-04 2004-08-04
US60/598,774 2004-08-04
US66870305P 2005-04-06 2005-04-06
US60/668,703 2005-04-06

Publications (2)

Publication Number Publication Date
WO2007001332A2 WO2007001332A2 (en) 2007-01-04
WO2007001332A3 true WO2007001332A3 (en) 2009-04-16

Family

ID=37595555

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027944 WO2007001332A2 (en) 2004-08-04 2005-08-04 Anti-pathogen immunoadhesins

Country Status (2)

Country Link
US (1) US8080245B2 (en)
WO (1) WO2007001332A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
EP2139992A4 (en) 2007-03-30 2011-08-10 Univ Duke A method of modulating the activity of a nucleic acid molecule
JP2012504651A (en) * 2008-10-02 2012-02-23 ヤンセン バイオテツク，インコーポレーテツド Methods for inhibiting Toll-like receptor activity
CN102639142A (en) * 2009-09-16 2012-08-15 杜克大学 Inhibition of endosomal toll-like receptor activation
SG182577A1 (en) 2010-01-19 2012-08-30 Harvard College Engineered opsonin for pathogen detection and treatment
DK2624873T3 (en) 2010-10-06 2020-03-02 Harvard College INJECTABLE, PORE-MAKING HYDROGLES FOR MATERIAL-BASED CELL THERAPIES
AU2012284097B2 (en) * 2011-07-18 2017-08-03 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
CA2865744A1 (en) * 2012-02-29 2013-09-06 President And Fellows Of Harvard College Rapid antibiotic susceptibility testing
EP2825554A2 (en) * 2012-03-12 2015-01-21 Scaratech Medical AB Chimeric proteins for treatment of diseases
SI2838515T1 (en) 2012-04-16 2020-07-31 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
US10551379B2 (en) 2013-03-15 2020-02-04 President And Fellows Of Harvard College Methods and compositions for improving detection and/or capture of a target entity
US10030067B2 (en) * 2013-03-15 2018-07-24 University Of Florida Research Foundation, Incorporated Compounds for treating neurodegenerative proteinopathies
CA2913155A1 (en) 2013-05-21 2014-11-27 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
WO2014190229A1 (en) * 2013-05-24 2014-11-27 President And Fellows Of Harvard College Methods of isolating microorganisms and uses thereof
EP3711484A1 (en) * 2013-07-05 2020-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
US10513546B2 (en) 2013-12-18 2019-12-24 President And Fellows Of Harvard College CRP capture/detection of gram positive bacteria
US10066323B2 (en) 2014-04-16 2018-09-04 Duke University Electrospun cationic nanofibers and methods of making and using the same
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
CN108289928A (en) 2015-08-06 2018-07-17 哈佛大学校长及研究员协会 Improved microorganism-binding molecule and its purposes
WO2017075189A1 (en) 2015-10-27 2017-05-04 University Of Massachusetts Factor h-fc immunotherapy
WO2017136837A1 (en) 2016-02-06 2017-08-10 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017143024A2 (en) * 2016-02-16 2017-08-24 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2020041590A1 (en) * 2018-08-23 2020-02-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tlr9 ligand trap
CN109762841B (en) * 2018-11-19 2021-03-02 厦门联合安金生物工程有限公司 BPI-Fc fusion protein and uses thereof
WO2021217113A1 (en) * 2020-04-25 2021-10-28 East Carolina University Compositions and methods of treating a coronavirus infection by use of an interferon fusion protein
WO2022232015A1 (en) * 2021-04-26 2022-11-03 East Carolina University Compositions and methods of treating pathogenic infections by using fusion proteins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462254B1 (en) * 1998-03-23 2002-10-08 Valentis, Inc. Dual-tagged proteins and their uses

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3137038A1 (en) * 1981-09-17 1983-03-24 Bayer Ag, 5090 Leverkusen SS-LACTAM ANTIBIOTIKA, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US5753227A (en) 1993-07-23 1998-05-19 Strahilevitz; Meir Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases
JPH09508359A (en) * 1994-01-14 1997-08-26 ゾーマ コーポレイション Anti-gram positive bacteriological methods and substances
US6107076A (en) * 1995-10-04 2000-08-22 Board Of Regents, The University Of Texas System Soluble mammalian adenylyl cyclase and uses therefor
US20030032090A1 (en) * 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
CA2388734A1 (en) 1999-09-01 2001-03-08 Human Genome Sciences, Inc. 37 staphylococcus aureus genes and polypeptides
CN102258784A (en) * 2003-05-15 2011-11-30 唐纳士公司 Methods and compositions for prevention and treatment of sepsis
WO2006025995A2 (en) * 2004-07-27 2006-03-09 The Regents Of The University Of California Compositions and methods using md-2 mutants and chimeric proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6462254B1 (en) * 1998-03-23 2002-10-08 Valentis, Inc. Dual-tagged proteins and their uses

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Abst Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicro Agents Chemother , September 14-17 2003", LUSANNE, SWITZERLAND, article FROIDEVAUX, R.T. ET AL.: "Anti-Toll Like Receptor 4 Antibodies Protect from Lethal Endotoxemia but Not from Gram-negative Septic Shock" *
LAWSON B.R., TREATMENT OF MURINE LUPUS WITH CDNA ENCODING IFN-GAMMAR/FC., vol. 106, 2000, pages 207 - 215 *
R & D SYSTEMS., RECOMBINANT MOUSE CD 14/FC CHIMERA. CATALOG NO: 982-CD., 10 October 2001 (2001-10-10), pages 1 *
ROBINSON C.R.: "Optimizing the Stability of Single Chain proteins by Linker Length and Composition Mutagenesis.", PROC. NATL. ACAD. SCI., vol. 95, May 1998 (1998-05-01), pages 5929 - 5934 *

Also Published As

Publication number Publication date
US20090208501A1 (en) 2009-08-20
US8080245B2 (en) 2011-12-20
WO2007001332A2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
WO2007001332A3 (en) Anti-pathogen immunoadhesins
WO2009068649A3 (en) Antigen-binding constructs
EA201990578A1 (en) BINDING MOLECULES THAT MODULATE THE CELL BIOLOGICAL ACTIVITY
MX2018013675A (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety.
EA201390923A1 (en) MODIFIED ANTIBODY WITH AN IMPROVED ELEMENTATION SEMIUM PERIOD
EA201100892A1 (en) PROTEINS CONNECTING WITH HUMAN CGRP RECEPTORS
WO2007121354A3 (en) Binding proteins comprising immunoglobulin hinge and fc regions having altered fc effector functions
EA201390146A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
EA201291181A1 (en) COMPOSITIONS AND METHODS OF APPLICATION OF THERAPEUTIC POLYVALENT ANTIBODIES AGAINST PROTEIN RELATED TO LOW DENSITY 6 LIPOPROTEIN RECEPTOR (LRP6)
DK2344540T3 (en) CD86 ANTAGONIST MULTIMARELY BINDING PROTEINS
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2006066078A3 (en) Fcϝriib-specific antibodies and methods of use thereof
DE602004025101D1 (en) HUMAN ANTI-HUMANE CD3 BONDING MOLECULES
PA8738401A1 (en) EXENDINE FUSION PROTEINS
PE20150023A1 (en) ST2 ANTIGEN BINDING PROTEINS
CR11030A (en) UNION PROTEINS, INCLUDING ANTIBODIES, DERIVATIVES OF ANTIBODIES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY JOIN CD154 AND ITS USES
NO20083497L (en) Modulation of bone formation
WO2011101681A3 (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
EP3255063A3 (en) Antibodies to matrix metalloproteinase 9
DK1742966T3 (en) Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2008098917A3 (en) Novel antibodies against igf-ir
UY30925A1 (en) IMMUNOGLOBULIN FUSION PROTEINS AND ELABORATION METHODS
EA200702193A1 (en) GLYCOSILIZATION BELKOV
EA201491575A1 (en) ANTIBODIES TO MATRIX METALLOPROTEINASE 9
EA200800301A1 (en) PROTEINS CONNECTING IL-6

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 11659154

Country of ref document: US